SAN DIEGO - May 21, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier® therapy.

The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of viral pathogens and tumor-secreted exosomes from the entire circulatory system to improve the benefit of drug therapies administered to infectious disease and cancer patients. In HCV care, the device is positioned to address drug resistance associated with emerging all-antiviral therapies and also targets to accelerate HCV RNA depletion at the outset of peginterferon+ribavirin (PR) therapy.

SHELTON, Conn. - May 21, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market announces Gino Pereira, CEO of NXT-ID, Inc., will demonstrate the functionality of its next generation smart wallet, Wocket™, designed to replace all the cards in your wallet, at the May 28th launch event at the Plaza in New York City.

The company also releases new product images and videos for the Wocket™ and the Wocket™ card at www.wocketwallet.com

NEW YORK and POINT ROBERTS, Washington - May 19, 2014 (Investorideas.com Newswire)

Verdi to Produce/Executive Produce Three Films with Oscar winning Director Martin Scorsese: Star studded actors include Liam Neeson, Andrew Garfield, Miles Teller, Aaron Eckhart and Adam Driver

"You may see a Wocket in a very famous Pocket" - C. Verdi

Investorideas.com, a global news source covering leading topics and sectors including technology and entertainment, releases an exclusive Q&A with entrepreneurial movie producer, businessman and investor Chad A. Verdi of Rhode Island.

SAN DIEGO - May 20, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon further announced that the Principal Investigator for this study will be Dr. Stephen Z. Fadem.

The clinical trial site location will be DaVita MedCenter Dialysis in Houston. Dr. Fadem is co-medical director of DaVita MedCenter Dialysis and this center is one of the three largest dialysis centers in the country with 72 treatment stations.